Illumina, Inc. (NASDAQ: ILMN) Stock Competitors & Peer Comparison
See ILMN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ILMN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ILMN | $272.00 | +0.04% | 41.2B | 54.08 | $5.03 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| TMO | $679.61 | +0.15% | 251.3B | 29.34 | $23.16 | +0.27% |
| DHR | $226.11 | -0.54% | 159B | 28.35 | $7.98 | +0.64% |
| NTRA | $414.52 | +0.67% | 59.4B | -314.03 | -$1.32 | N/A |
| A | $175.03 | -0.10% | 49.4B | 30.12 | $5.81 | +0.58% |
| IQV | $268.99 | -0.73% | 44.3B | 22.19 | $12.13 | N/A |
| WAT | $443.26 | +0.07% | 43.5B | 32.42 | $13.68 | N/A |
| IDXX | $533.44 | +0.83% | 42.1B | 37.51 | $14.22 | N/A |
| MTD | $1,537.33 | -0.51% | 31.1B | 35.36 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
ILMN vs DHR-PB Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, ILMN's ROE is +0.31%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, ILMN is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
ILMN vs TMO Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, TMO has a market cap of 251.3B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while TMO trades at $679.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas TMO's P/E ratio is 29.34. In terms of profitability, ILMN's ROE is +0.31%, compared to TMO's ROE of +0.13%. Regarding short-term risk, ILMN is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
ILMN vs DHR Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, DHR has a market cap of 159B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while DHR trades at $226.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas DHR's P/E ratio is 28.35. In terms of profitability, ILMN's ROE is +0.31%, compared to DHR's ROE of +0.08%. Regarding short-term risk, ILMN is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
ILMN vs NTRA Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, NTRA has a market cap of 59.4B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while NTRA trades at $414.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas NTRA's P/E ratio is -314.03. In terms of profitability, ILMN's ROE is +0.31%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, ILMN is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
ILMN vs A Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, A has a market cap of 49.4B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while A trades at $175.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas A's P/E ratio is 30.12. In terms of profitability, ILMN's ROE is +0.31%, compared to A's ROE of +0.20%. Regarding short-term risk, ILMN is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
ILMN vs IQV Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, IQV has a market cap of 44.3B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while IQV trades at $268.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas IQV's P/E ratio is 22.19. In terms of profitability, ILMN's ROE is +0.31%, compared to IQV's ROE of +0.22%. Regarding short-term risk, ILMN is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check IQV's competition here
Waters Corporation (NYSE: WAT)
ILMN vs WAT Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while WAT trades at $443.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas WAT's P/E ratio is 32.42. In terms of profitability, ILMN's ROE is +0.31%, compared to WAT's ROE of +0.02%. Regarding short-term risk, ILMN is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
ILMN vs IDXX Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, IDXX has a market cap of 42.1B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while IDXX trades at $533.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas IDXX's P/E ratio is 37.51. In terms of profitability, ILMN's ROE is +0.31%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, ILMN is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
ILMN vs MTD Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, MTD has a market cap of 31.1B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while MTD trades at $1,537.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas MTD's P/E ratio is 35.36. In terms of profitability, ILMN's ROE is +0.31%, compared to MTD's ROE of -12.00%. Regarding short-term risk, ILMN is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
ILMN vs DGX Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, DGX has a market cap of 25.6B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while DGX trades at $231.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas DGX's P/E ratio is 22.87. In terms of profitability, ILMN's ROE is +0.31%, compared to DGX's ROE of +0.14%. Regarding short-term risk, ILMN is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
ILMN vs LH Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, LH has a market cap of 25.3B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while LH trades at $308.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas LH's P/E ratio is 18.33. In terms of profitability, ILMN's ROE is +0.31%, compared to LH's ROE of +0.12%. Regarding short-term risk, ILMN is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
ILMN vs GH Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, GH has a market cap of 23.9B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while GH trades at $177.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas GH's P/E ratio is -50.93. In terms of profitability, ILMN's ROE is +0.31%, compared to GH's ROE of +2.11%. Regarding short-term risk, ILMN is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
ILMN vs EXAS Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas EXAS's P/E ratio is -95.37. In terms of profitability, ILMN's ROE is +0.31%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, ILMN is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
ILMN vs MEDP Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, MEDP has a market cap of 17.4B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while MEDP trades at $622.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas MEDP's P/E ratio is 36.47. In terms of profitability, ILMN's ROE is +0.31%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, ILMN is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
ILMN vs RVTY Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, RVTY has a market cap of 17B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while RVTY trades at $152.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas RVTY's P/E ratio is 28.55. In terms of profitability, ILMN's ROE is +0.31%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, ILMN is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
ILMN vs ILMNV Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas ILMNV's P/E ratio is N/A. In terms of profitability, ILMN's ROE is +0.31%, compared to ILMNV's ROE of N/A. Regarding short-term risk, ILMN is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
ILMN vs PKI Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas PKI's P/E ratio is 41.45. In terms of profitability, ILMN's ROE is +0.31%, compared to PKI's ROE of +0.03%. Regarding short-term risk, ILMN is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
ILMN vs CRL Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, CRL has a market cap of 14.3B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while CRL trades at $295.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas CRL's P/E ratio is 29.91. In terms of profitability, ILMN's ROE is +0.31%, compared to CRL's ROE of -0.08%. Regarding short-term risk, ILMN is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
ILMN vs ICLR Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, ICLR has a market cap of 13B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while ICLR trades at $170.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas ICLR's P/E ratio is 13.89. In terms of profitability, ILMN's ROE is +0.31%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, ILMN is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
ILMN vs QGEN Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, QGEN has a market cap of 9.2B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while QGEN trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas QGEN's P/E ratio is 18.34. In terms of profitability, ILMN's ROE is +0.31%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, ILMN is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
ILMN vs GRAL Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while GRAL trades at $136.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas GRAL's P/E ratio is -14.01. In terms of profitability, ILMN's ROE is +0.31%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, ILMN is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
ILMN vs RDNT Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while RDNT trades at $70.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas RDNT's P/E ratio is 153.59. In terms of profitability, ILMN's ROE is +0.31%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, ILMN is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
ILMN vs BLLN Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while BLLN trades at $118.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas BLLN's P/E ratio is 168.83. In terms of profitability, ILMN's ROE is +0.31%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, ILMN is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
ILMN vs SHC Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while SHC trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas SHC's P/E ratio is 19.38. In terms of profitability, ILMN's ROE is +0.31%, compared to SHC's ROE of +0.27%. Regarding short-term risk, ILMN is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
ILMN vs SYNH Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas SYNH's P/E ratio is 61.40. In terms of profitability, ILMN's ROE is +0.31%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, ILMN is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
ILMN vs VCYT Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while VCYT trades at $46.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas VCYT's P/E ratio is 23.04. In terms of profitability, ILMN's ROE is +0.31%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, ILMN is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
ILMN vs CDNA Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while CDNA trades at $64.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas CDNA's P/E ratio is 76.21. In terms of profitability, ILMN's ROE is +0.31%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, ILMN is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
ILMN vs OLK Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas OLK's P/E ratio is -96.59. In terms of profitability, ILMN's ROE is +0.31%, compared to OLK's ROE of -0.07%. Regarding short-term risk, ILMN is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
ILMN vs WGS Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while WGS trades at $75.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas WGS's P/E ratio is 210.53. In terms of profitability, ILMN's ROE is +0.31%, compared to WGS's ROE of -0.39%. Regarding short-term risk, ILMN is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
ILMN vs PSNL Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while PSNL trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas PSNL's P/E ratio is -15.00. In terms of profitability, ILMN's ROE is +0.31%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, ILMN is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
ILMN vs OPK Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while OPK trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas OPK's P/E ratio is -6.00. In terms of profitability, ILMN's ROE is +0.31%, compared to OPK's ROE of -0.06%. Regarding short-term risk, ILMN is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
ILMN vs CSTL Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while CSTL trades at $34.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas CSTL's P/E ratio is -52.85. In terms of profitability, ILMN's ROE is +0.31%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, ILMN is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
ILMN vs FLGT Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, FLGT has a market cap of 627.1M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while FLGT trades at $22.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas FLGT's P/E ratio is 2208.00. In terms of profitability, ILMN's ROE is +0.31%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, ILMN is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
ILMN vs GRALV Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas GRALV's P/E ratio is N/A. In terms of profitability, ILMN's ROE is +0.31%, compared to GRALV's ROE of N/A. Regarding short-term risk, ILMN is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
ILMN vs NEO Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, NEO has a market cap of 481.5M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while NEO trades at $18.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas NEO's P/E ratio is 144.15. In terms of profitability, ILMN's ROE is +0.31%, compared to NEO's ROE of -0.06%. Regarding short-term risk, ILMN is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
ILMN vs CO Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas CO's P/E ratio is 5.06. In terms of profitability, ILMN's ROE is +0.31%, compared to CO's ROE of +0.11%. Regarding short-term risk, ILMN is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
ILMN vs MYGN Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, MYGN has a market cap of 399.5M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while MYGN trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas MYGN's P/E ratio is -32.54. In terms of profitability, ILMN's ROE is +0.31%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, ILMN is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
ILMN vs FLDM Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas FLDM's P/E ratio is -4.74. In terms of profitability, ILMN's ROE is +0.31%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, ILMN is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
ILMN vs BDSX Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, BDSX has a market cap of 237.2M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while BDSX trades at $29.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas BDSX's P/E ratio is -9.19. In terms of profitability, ILMN's ROE is +0.31%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, ILMN is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
ILMN vs XGN Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, XGN has a market cap of 204.9M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while XGN trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas XGN's P/E ratio is -10.47. In terms of profitability, ILMN's ROE is +0.31%, compared to XGN's ROE of -1.22%. Regarding short-term risk, ILMN is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
ILMN vs FRNM Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, FRNM has a market cap of 129.9M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while FRNM trades at $15.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas FRNM's P/E ratio is N/A. In terms of profitability, ILMN's ROE is +0.31%, compared to FRNM's ROE of N/A. Regarding short-term risk, ILMN is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
ILMN vs GTH Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas GTH's P/E ratio is -1.11. In terms of profitability, ILMN's ROE is +0.31%, compared to GTH's ROE of -1.01%. Regarding short-term risk, ILMN is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
ILMN vs GENE Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas GENE's P/E ratio is -38.25. In terms of profitability, ILMN's ROE is +0.31%, compared to GENE's ROE of -1.85%. Regarding short-term risk, ILMN is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
ILMN vs IMDX Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas IMDX's P/E ratio is -2.27. In terms of profitability, ILMN's ROE is +0.31%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, ILMN is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
ILMN vs SERA Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while SERA trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas SERA's P/E ratio is -3.15. In terms of profitability, ILMN's ROE is +0.31%, compared to SERA's ROE of -0.47%. Regarding short-term risk, ILMN is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
ILMN vs PRPO Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, PRPO has a market cap of 42.1M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while PRPO trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas PRPO's P/E ratio is -36.28. In terms of profitability, ILMN's ROE is +0.31%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, ILMN is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
ILMN vs QUCY Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas QUCY's P/E ratio is -0.06. In terms of profitability, ILMN's ROE is +0.31%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, ILMN is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
ILMN vs MDXH Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, MDXH has a market cap of 26.7M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while MDXH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas MDXH's P/E ratio is -0.71. In terms of profitability, ILMN's ROE is +0.31%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, ILMN is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
ILMN vs AKU Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas AKU's P/E ratio is -0.13. In terms of profitability, ILMN's ROE is +0.31%, compared to AKU's ROE of -5.32%. Regarding short-term risk, ILMN is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
ILMN vs BNR Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, BNR has a market cap of 20M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while BNR trades at $18.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas BNR's P/E ratio is -21.77. In terms of profitability, ILMN's ROE is +0.31%, compared to BNR's ROE of -0.13%. Regarding short-term risk, ILMN is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
ILMN vs CEMI Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas CEMI's P/E ratio is -0.63. In terms of profitability, ILMN's ROE is +0.31%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, ILMN is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
ILMN vs ENZ Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas ENZ's P/E ratio is -2.24. In terms of profitability, ILMN's ROE is +0.31%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, ILMN is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
ILMN vs PMD Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas PMD's P/E ratio is -5.24. In terms of profitability, ILMN's ROE is +0.31%, compared to PMD's ROE of -0.32%. Regarding short-term risk, ILMN is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
ILMN vs ME Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas ME's P/E ratio is -0.03. In terms of profitability, ILMN's ROE is +0.31%, compared to ME's ROE of -42.03%. Regarding short-term risk, ILMN is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
ILMN vs MYNZ Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, ILMN's ROE is +0.31%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, ILMN is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
ILMN vs BIAFW Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, BIAFW has a market cap of 11.4M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while BIAFW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas BIAFW's P/E ratio is 1.21. In terms of profitability, ILMN's ROE is +0.31%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, ILMN is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
ILMN vs CHEK Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas CHEK's P/E ratio is -0.43. In terms of profitability, ILMN's ROE is +0.31%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, ILMN is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
ILMN vs CNTG Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas CNTG's P/E ratio is -0.23. In terms of profitability, ILMN's ROE is +0.31%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, ILMN is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
ILMN vs ADVB Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while ADVB trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas ADVB's P/E ratio is -57.45. In terms of profitability, ILMN's ROE is +0.31%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, ILMN is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
ILMN vs NDRA Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while NDRA trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas NDRA's P/E ratio is -0.88. In terms of profitability, ILMN's ROE is +0.31%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, ILMN is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
ILMN vs APDN Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas APDN's P/E ratio is -0.10. In terms of profitability, ILMN's ROE is +0.31%, compared to APDN's ROE of -7.23%. Regarding short-term risk, ILMN is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
ILMN vs NVTA Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas NVTA's P/E ratio is -0.00. In terms of profitability, ILMN's ROE is +0.31%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, ILMN is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
ILMN vs LMDX Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas LMDX's P/E ratio is -0.01. In terms of profitability, ILMN's ROE is +0.31%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, ILMN is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
ILMN vs LMDXW Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, ILMN's ROE is +0.31%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, ILMN is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
ILMN vs DMTK Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas DMTK's P/E ratio is -0.04. In terms of profitability, ILMN's ROE is +0.31%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, ILMN is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check DMTK's competition here
iSpecimen Inc. (NASDAQ: ISPC)
ILMN vs ISPC Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, ISPC has a market cap of 3M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while ISPC trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas ISPC's P/E ratio is -0.04. In terms of profitability, ILMN's ROE is +0.31%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, ILMN is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
ILMN vs BIAF Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, BIAF has a market cap of 2.9M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while BIAF trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas BIAF's P/E ratio is -0.81. In terms of profitability, ILMN's ROE is +0.31%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, ILMN is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
ILMN vs NOTV Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas NOTV's P/E ratio is -0.03. In terms of profitability, ILMN's ROE is +0.31%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, ILMN is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
ILMN vs SQL Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas SQL's P/E ratio is -0.40. In terms of profitability, ILMN's ROE is +0.31%, compared to SQL's ROE of -30.46%. Regarding short-term risk, ILMN is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
ILMN vs AWH Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas AWH's P/E ratio is -0.09. In terms of profitability, ILMN's ROE is +0.31%, compared to AWH's ROE of +1.62%. Regarding short-term risk, ILMN is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
ILMN vs HTGM Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas HTGM's P/E ratio is -0.03. In terms of profitability, ILMN's ROE is +0.31%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, ILMN is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
ILMN vs BIOC Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas BIOC's P/E ratio is -0.01. In terms of profitability, ILMN's ROE is +0.31%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, ILMN is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
ILMN vs SQLLW Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, ILMN's ROE is +0.31%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, ILMN is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
ILMN vs WGSWW Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, ILMN's ROE is +0.31%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, ILMN is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check WGSWW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
ILMN vs CHEKZ Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, ILMN's ROE is +0.31%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, ILMN is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check CHEKZ's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
ILMN vs PRXL Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas PRXL's P/E ratio is 42.97. In terms of profitability, ILMN's ROE is +0.31%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, ILMN is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check PRXL's competition here
Danaher Corporation (NYSE: DHR-PA)
ILMN vs DHR-PA Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, ILMN's ROE is +0.31%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, ILMN is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
ILMN vs OCDX Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas OCDX's P/E ratio is -42.28. In terms of profitability, ILMN's ROE is +0.31%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, ILMN is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for ILMN.Check OCDX's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
ILMN vs NDRAW Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas NDRAW's P/E ratio is N/A. In terms of profitability, ILMN's ROE is +0.31%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, ILMN is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
ILMN vs MEUSW Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas MEUSW's P/E ratio is N/A. In terms of profitability, ILMN's ROE is +0.31%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, ILMN is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
ILMN vs BNGOW Comparison September 2026
Illumina, Inc. (NASDAQ: ILMN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ILMN stands at 41.2B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, ILMN is priced at $272.00 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ILMN currently has a P/E ratio of 54.08, whereas BNGOW's P/E ratio is N/A. In terms of profitability, ILMN's ROE is +0.31%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, ILMN is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for ILMN.Check BNGOW's competition here